Wpływ pionowej plastyki żołądka na masę ciała, insulinooporność, adipocytokiny oraz na czynniki zapalne i wskaźniki zespołu metabolicznego u chorych z otyłością olbrzymią by Jankiewicz-Wika, Joanna et al.
109
PRACE ORYGINALNE/ORIGINAL PAPERS
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 2/2011
ISSN 0423–104X
Jan Komorowski MD, PhD, Department of Clinical Endocrinology, Medical University of Łódź, Sterlinga St. 3, 91–425 Łódź, Poland,
tel.: + 48 42 633 19 31, fax: + 48 42 636 54 27, e-mail: jan.komorowski@umed.lodz.pl
Impact of vertical banded gastroplasty on body weight,
insulin resistance, adipocytokine, inflammation and
metabolic syndrome markers in morbidly obese patients
Wpływ pionowej plastyki żołądka na masę ciała, insulinooporność,
adipocytokiny oraz na czynniki zapalne i wskaźniki zespołu metabolicznego
u chorych z otyłością olbrzymią
Joanna Jankiewicz-Wika1, Krzysztof Kołomecki2, Jacek Cywiński3, Katarzyna Piestrzeniewicz4,
Jacek Świętosławski5, Henryk Stępień6, Jan Komorowski1
1Department of Clinical Endocrinology, First Chair of Endocrinology, Medical University, Łódź, Poland
2Department of Endocrine, Vascular and General Surgery, First Chair of Endocrinology, Medical University, Łódź, Poland
3Department of General Surgery, Nicolaus Copernicus Hospital, Łódź, Poland
4First Department of Cardiology, Medical University, Łódź, Poland
5Department of Neuroendocrinology, Medical University, Łódź, Poland
6Department of Immunoendocrinology, First Chair of Endocrinology, Medical University, Łódź, Poland
Abstract
Introduction: Diet, exercise, and pharmacological therapy have been shown to be unsatisfactory treatments for severe obesity in the long
term. Bariatric surgery is the most effective means to achieve weight loss in morbidly obese subjects.
The aim of this study was to evaluate the action of a number of adipocytokines, as well as the metabolic syndrome parameters of obese
patients, before and after vertical banded gastroplasty (VBG).
Material and methods: The test subjects comprised eight males and 20 females (total 28 patients) aged from 20 to 59 years (43.7 ± 10.0)
with simple obesity and the presence of metabolic syndrome, both before and 3, 6, 12, and 24 months after bariatric surgery (six patients
were also checked after 36 and 48 months).
Results: After surgical treatment (at 24 months), the values of body weight, BMI, waist circumference, blood pressure (RR-S, RR-D),
HOMA-IR and blood concentrations of CRP, TG, IRI, AUC-IRI, and AUC-GLU gradually decreased. We did not observe any significant
differences of fasting glucose, leptin, total cholesterol and LDL-cholesterol concentrations before or after surgery. The blood levels of HDL,
adiponectin, resistin, and ghrelin gradually increased after treatment.
Conclusions: The significant decrease of body weight after vertical banded gastroplasty, as well as improvement of the main metabolic
syndrome parameters and some adipocytokine blood levels, indicate the use of bariatric surgery as a valuable method of treating morbidly
obese patients. (Pol J Endocrinol 2011; 62 (2): 109–119)
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Streszczenie
Wstęp: Dieta, ćwiczenia fizyczne i zastosowanie leczenia farmakologicznego nie powodują długotrwałej redukcji masy ciała u pacjentów
otyłych. Skuteczne w tym zakresie okazały się natomiast bariatryczne zabiegi operacyjne.
Celem pracy była ocena zmian w zakresie parametrów zespołu metabolicznego i stężenia niektórych adipocytokin u chorych ze znaczne-
go stopnia otyłością leczonych za pomocą pionowej plastyki żołądka (VBG).
Materiał i metody: Dwudziestu ośmiu chorych (8 mężczyzn i 20 kobiet) w wieku 20–59 lat (43,7 ± 10,0) z otyłością prostą powikłaną
zespołem metabolicznym badano przed i po 3, 6, 12 i 24 miesiącach (6 chorych oceniano także po 36 i 48 miesiącach) od operacji bariatrycznej.
Wyniki: Po leczeniu operacyjnym (po 24 miesiącach) zaobserwowano stopniowe zmniejszanie masy ciała, BMI, obwodu talii, skurczowego
i rozkurczowego ciśnienia tętniczego (RR-S, RR-D), wartości wskaźnika insulinooporności (HOMA-IR) oraz stężeń we krwi: CRP, triglice-
rydów (TG), insuliny (IRI), glikemii (AUC-GLU) oraz mobilizacji wydzielania insuliny po glukozie (AUC-IRI). Nie stwierdzono zmian
w zakresie stężeń glukozy (0’), leptyny, cholesterolu całkowitego i cholesterolu frakcji LDL. Natomiast po operacji stopniowo narastały
stężenia: cholesterolu frakcji HDL, adiponektyny, rezystyny oraz greliny we krwi żylnej.
Wnioski: Po pionowej plastyce żołądka zaobserwowano znaczną redukcję masy ciała i poprawę w zakresie parametrów zespołu metabo-
licznego oraz profilu wydzielania niektórych adipocytokin. Uzyskane wyniki potwierdzają przydatność tego typu operacji bariatrycznej
w leczeniu chorych z otyłością olbrzymią. (Endokrynol Pol 2011; 62 (2): 109–119)
Słowa kluczowe: otyłość olbrzymia, zespół metaboliczny, operacje bariatryczne, adiponektyna, leptyna, rezystyna, grelina
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Introduction
The prevalence of overweight and obesity has increased
steadily in all Western countries, especially the United
States [1–3]. Severe obesity is a risk factor for multiple
serious health problems in adults, including heart dis-
ease, hardening of the arteries, high cholesterol, high
blood pressure, certain types of cancer, stroke, diabetes,
muscle and bone disorders and gall bladder disease [4].
Causes of obesity include the wide availability of
unhealthy foods, increased consumption, changing eat-
ing habits, high-calorie beverages and lack of physical
activity. In the USA, total healthcare costs attributable
to obesity/overweight are predicted to double each de-
cade, reaching $860.7–956.9 billion by 2030, accounting
for 16–18% of total USA healthcare expenditure [3].
Overweight and obesity continue to climb steadily, not
only in the United States but also to a lesser degree in
Europe, among both adults and children, increasing the
risk of a host of physical, psychosocial and economic
problems.
In 2007–2008, the prevalence of obesity in the US was
32.2% among adult men and 35.5% among adult women
[1, 2, 5]. More than half of the European population is
overweight (body mass index (BMI) > 25 and < 30 kg/m2)
and up to 30% are obese (BMI ≥ 30 kg/m2). Furthermore,
21% of the male and 22% of the female population of
Poland is obese (Polish National Multicentre Health
Survey WOBASZ study 2002–2005).
Obesity is closely associated not only with insulin
resistance but also with elevated triglyceride levels, low
HDL and high LDL cholesterol levels and elevated
blood pressure; it produces a complex of medical con-
ditions known as the metabolic syndrome [6, 7] leading to
atherosclerosis. The development of the metabolic syn-
drome, involving a complex set of risk factors including
glucose intolerance, hyperinsulinaemia, hypertension,
and dyslipidaemia, dramatically heightens cardiovas-
cular risk.
The National Cholesterol Educational Programme
(Adult Treatment Panel III-ATP III) and other authors
have suggested the use of the term metabolic syndrome
to identify a common cluster of metabolic abnormali-
ties, defined when at least three of five criteria are met:
— abdominal obesity (waist circumference, > 102 cm
in men and > 88 cm in women)
— hypertriglyceridemia (≥ 150 mg/dL)
— low HDL (< 40 mg/dl in men and < 50 mg/dL in
women)
— hypertension (≥ 130/85 mm Hg)
— elevated fasting glucose (≥ 110 mg/dL) [8–11].
According to International Diabetes Federation (IDF
2005) criteria, in order to be diagnosed as having meta-
bolic syndrome, patients have to demonstrate abdomi-
nal obesity (waist circumference ≥ 94 cm in men and
≥ 80 cm in women) and fulfill at least two of four criteria:
— triglyceride concentration ≥ 150 mg/dL or treatment
of hypertriglyceridemia
— concentration of cholesterol of HDL fraction < 40 mg/
/dL in men and < 50 mg/dL in women or dyslipi-
demia treatment
— systolic blood pressure (SBP) ≥ 130 mm Hg or dias-
tolic blood pressure (DBP) ≥ 85 mm Hg or hyper-
tension
— fasting glucose concentration in plasma ≥ 100 mg/dL
or diagnosed type 2 diabetes.
Visceral fat accumulation in the abdomen is a po-
tent modulator of insulin action on hepatic glucose pro-
duction [12]. Human fat tissue is also able to produce
several hormonal factors such as leptin, adiponectin and
resistin, known as the adipocytokines or adipokines,
which influence the development and severity of the
clinical outcome of the metabolic syndrome [13, 14].
At present, bariatric surgery is the most effective
method used to achieve long-term weight loss, the
major goal in obesity treatment. It has been document-
ed that post-surgical weight loss improves almost all
obesity-related comorbidities [15–20].
The aim of our study was to evaluate a number of
anthropometric parameters, some adipocytokines, gh-
relin, insulin resistance markers, as well as the parame-
ters of metabolic syndrome in morbidly obese patients
for 3, 6, 12, 24, 36 and 48 months after vertical banded
gastroplasty.
Material and methods
Eight males and twenty females (total 28 patients) aged
from 20 to 59 years (43.7 ± 10.0) with simple obesity
and the presence of metabolic syndrome (both by ATP
III and IDF 2005 criteria) were studied both before and
three, six, 12 and 24 months after bariatric surgery (six
patients were also checked after 36 and 48 months).
Blood samples were drawn in the morning after
an overnight fast, using EDTA as anticoagulant. Blood
plasma leptin (DSL, USA kit; sensitivity-0.05 ng/mL;
intra-assay precision — 3.0%, inter-assay precision
— 3.4%), adiponectin (R & D Systems kit, USA; sensi-
tivity — 0.25 ng/mL; intra-assay precision — 4.7%, in-
ter-assay precision — 7.9%), resistin (R & D Systems
kit, USA; sensitivity — 0.026 ng/mL; intra-assay preci-
sion — 5.3%, inter-assay precision — 8.2%) and serum
ghrelin (DSL kit, USA; sensitivity — 0.09 ng/mL; intra-
assay and inter-assay precision — < 10%) concentra-
tions before and after treatment were evaluated by
ELISA and plasma insulin (IRI) by MEIA (Abbott, Ax-
sym System, USA; sensitivity < 1 mU/mL; intra-assay
precision — 2.6%, inter-assay precision — 2.9%) methods.
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Blood glucose, high-density lipoprotein (HDL), low-
-density lipoprotein (LDL), triglycerides, and high sen-
sitivity C-reactive protein (CRP-using high sensitivity
assay) were analysed. CRP and lipids were evaluated
by COBAS INTEGRA Roche Diagnostics (Hitachi 912/
/917). Furthermore, systolic (RR-S) and diastolic (RR-D)
blood pressure (patients were without any hypotensive
medication) as well as the body mass index (BMI) were
measured. Waist circumference and the homeostasis
model assessment insulin resistance index [HOMA-IR =
= fasting insulin (mIU/L) × × fasting glucose (mmol/L)
22.5] were calculated.
Statistical analysis
All comparisons were carried out using Statistica 8.0
software. The Student’s paired t-test was used. The re-
lationship between features was evaluated using the
Pearson’s correlation coefficient analysis. The values are
presented as the mean ± SEM. A p value £ 0.05 or less
was considered statistically significant.
The study was approved by the Local Ethics Com-
mittee of the Medical University of Lodz.
Results
After surgical treatment (at 24 months), the values of
BMI, waist circumference, RR-S, RR-D, HOMA-IR and
blood concentrations of CRP, TG, IRI, AUC-IRI, and
AUC-GLU gradually decreased (Figs. 1– 4). We did not
observe any significant differences of fasting glucose,
leptin, total cholesterol and LDL-cholesterol concentra-
tions before or after surgery. The blood levels of HDL,
adiponectin, resistin, and ghrelin gradually increased
after treatment (Fig. 5).
The positive and negative correlations between the
parameters studied 3, 6, 12, and 24 months after VBG
are given in Table I and Table II respectively.
Discussion
The evidence indicates that bariatric surgery is a more
effective intervention for weight loss than non-surgical
options. Diet, exercise, and pharmacological therapy
have not been shown to be satisfactory methods in treat-
Figure 1. Anthropometric data: body weight, BMI, body mass reduction (%), waist circumference of obese patients before and after
surgery (m = months; x ± SEM; *p < 0.05; ***p < 0.001 vs. before surgery)
Rycina 1. Dane antropometryczne: masa ciała, BMI, stopień redukcji masy ciała (%), obwód talii u otyłych pacjentów przed i po
leczeniu bariatrycznym (m = miesiące; x ± SEM; *p < 0,05; ***p < 0,001 v. przed operacją)
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Figure 2. Peripheral blood concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density (LDL) cholesterol
and triglycerides in obese patients before and after surgery (m = months; x ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. before
surgery)
Rycina 2. Stężenia: całkowitego cholesterolu, HDL-cholesterolu (HDL), LDL-cholesterolu (LDL) i triglicerydów w obwodowej krwi żylnej
u otyłych pacjentów przed i po leczeniu bariatrycznym (m = miesiące; x ± SEM; *p < 0,05; **p < 0,01; ***p < 0,001 v. przed operacją)
ing severe obesity in the long term [21, 22]. This, and
the steep rise in the prevalence of severe obesity lap-
aroscopic procedures, may explain the exponential in-
crease in the number of bariatric surgeries performed
in the USA from 13,365 in 1998 to 72,177 in 2002 [23], to
130,000 in 2005. An estimated 220,000 people underwent
bariatric surgical procedures in the United States in 2008
(American Society for Bariatric Surgery 2009). The var-
ious types of bariatric procedures include Roux-en-Y
gastric bypass (RYGB), gastric banding (GB), vertical
banded gastroplasty (VBG), duodenal switch, biliopan-
creatic diversion, isolated intestinal bypass, and gastrec-
tomy. Recently, RYGB and GB surgeries have been the
most commonly performed (24) but vertical banded
gastroplasty is the primary focus of this study. Gastric
bypass (GBP) is more effective for weight loss than ver-
tical banded gastroplasty (VBG) and adjustable gastric
banding (AGB) [25].
According to a recent metaanalysis on bariatric sur-
gery outcomes [26], patients who undergo bariatric sur-
geries lose up to 61.6% of their excess body weight, and
a majority of patients with diabetes, hyperlipidaemia,
hypertension, and obstructive sleep apnea experience
complete resolution or improvement of these comorbid-
ities. However, most of the studies included in the
metaanalysis were uncontrolled case series, and patients
were followed up for no more than two years. Emerging
data, however, suggests some gradual weight regain and
return of comorbidities in the long term [27]. Maximum
weight losses in the surgical subgroups were observed
by Sjostrom et al. [28] after one to two years: gastric by-
pass, 32%; vertical banded gastroplasty, 25%; and band-
ing, 20%. After ten years, the weight losses from baseline
were stabilised at 25%, 16%, and 14%, respectively.
In the present study, we examined the effect of
weight loss surgery (VBG) on changes in body compo-
sition (BMI, waist circumference), metabolic, inflamma-
tion and adipokine markers over 24 months. These pa-
rameters were also checked at 36 and 48 months in six
subjects who completed the study, to confirm whether
the trends demonstrated by the obtained results are sim-
ilar over a longer term.
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The effectiveness of bariatric surgery has recently
been studied in two meta-analyses [26, 29]. On aver-
age, surgical treatment of obesity results in 20–40 kg of
weight loss (similar to our results) and a 10–15 kg/m2
reduction in BMI [26, 29]. In the Swedish Obesity Study
(SOS), the average ten-year weight loss was well over
19 kg [27]. This result was achieved despite the fact that
vertical banded gastroplasty was the dominant proce-
dure and only 5% of those who had a follow-up of ten
years had a Roux-en-Y gastric bypass (which is superi-
or to vertical banded gastroplasty regarding weight loss)
[27]. After a period of 15 years, patients who had un-
dergone laparoscopic gastric banding had lost 13±14%
compared with the baseline weight. Corresponding
weight losses 15 years after vertical banded gastroplas-
ty and Roux-en-Y gastric bypass were 18 ± 11% and
27±12% respectively [28].
Few studies have compared weight loss between
surgical procedures. In two randomised clinical trials
collectively enrolling 231 patients, Roux-en-Y gastric
bypass was compared with vertical banded gastroplas-
ty [29–31]. Pooled results showed that at 12 and 36
months, patients assigned to Roux-en-Y gastric bypass
lost substantially more weight than those assigned to
vertical banded gastroplasty (42.43 kg versus 34.45 kg
and 39.73 kg versus 30.65 kg at 12 and 36 months re-
spectively) [29–31].
On the basis of these and other studies [32–34], it
can be concluded that in regard to weight loss, Roux-
en-Y gastric bypass is superior to vertical banded gas-
troplasty. Recently, laparoscopic adjustable gastric band-
ing was compared to laparoscopic vertical banded gas-
troplasty in a randomized trial involving 100 patients
[35]. In this study, excess weight loss was 58.9% three
years after laparoscopic vertical banded gastroplasty and
39% three years after laparoscopic adjustable gastric
banding [35].
Several studies using homeostatic model assessment
have reported improvements in insulin sensitivity and
b-cell function [36, 37]. These sets of data are substantiat-
ed by studies that have used euglycemic–hyperinsuli-
naemic clamp and i.v. glucose tolerance testing [38, 39].
Even normal weight individuals with increased amounts
of abdominal adipose tissue can be metabolically obese,
with insulin resistance and dyslipidaemia [40, 41].
Hypercholesterolaemia and hypertriglyceridaemia
improve after surgical treatment of obesity, irrespective
of the technique used [26]. Total and low density lipo-
Figure 3. Data concerning HOMA-IR, CRP, and systolic and diastolic blood pressure (RR-S, RR-D) in obese patients before and after
surgery (m = months; x ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. before surgery)
Rycina 3. Dane dotyczące wartości: HOMA-IR, CRP, skurczowego (RR-S) i rozkurczowego (RR-D) ciśnienia krwi u otyłych pacjentów
przed i po leczeniu bariatrycznym (m = miesiące; x ± SEM; *p < 0,05; **p < 0,01; ***p < 0,001 v. przed operacją)
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protein (LDL) cholesterol concentrations decreased with
an average of 0.86 mmol/L (95% confidence interval (CI)
0.60–1.13 mmol/L) and 0.76 mmol/L (95% CI 0.46–1.06
mmol/L) respectively (26). While triglyceride concentra-
tions decreased with an average of 0.90 mmol/L (95%
CI 0.73–1.08 mmol/L), high density lipoprotein (HDL)
cholesterol concentration showed no difference in
a combined analysis of all surgical procedures (26). How-
ever, patients who underwent vertical banded gastro-
plasty (n = 253) or gastric banding (n = 623) showed an
increase in concentration of HDL cholesterol of
0.13 mmol/L (95% CI 0.02–0.24 mmol/L) and 0.12 mmol/L
(95% CI 0.04–0.20 mmol/L) respectively [26]. The study
highlights another benefit concerned with surgery:
a reduction of the prevalence of hypertension [26]. Of
the surgically treated patients, 62% of those with hy-
pertension recovered [26].
Leptin is the product of the obese (ob) gene and is
generated predominantly in white adipose tissue [42].
It is involved in the maintenance of energy balance and
body weight. In humans, peripheral blood leptin con-
centration is strongly correlated with the amount of
body fat and body mass index [43]. The arcuate nucle-
us (ARC) of the hypothalamus serves as the leptin sig-
nalling centre. It is known that the insulin/leptin-arcu-
ate nucleus of the hypothalamus axis regulates energy
homeostasis through control of appetite and energy
expenditure. Both hormones rise in direct proportion
to adipose mass; they cross the blood-brain barrier and
have receptors in the ARC [44]. The circulating leptin
levels serve as a gauge of energy stores, thereby direct-
ing the regulation of energy homeostasis, neuroendo-
crine function, and metabolism. Persons with a congen-
ital deficiency are obese, and treatment with leptin re-
sults in dramatic weight loss through decreased food
intake and possible increased energy expenditure.
However, most obese persons are resistant to the
weight-reducing effects of leptin [45]. Recent studies
suggest that leptin is physiologically more important
as an indicator of energy deficiency, rather than ener-
gy excess, and may mediate adaptation by driving in-
creased food intake and directing neuroendocrine func-
Figure 4. Peripheral blood concentrations of glucose, insulin as well as glucose and insulin mobilisation after 75 g oral glucose (AUC-
GLU, AUC-IRI) in obese patients before and after surgery (m = months; x ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. before
surgery)
Rycina 4. Stężenia: glukozy, insuliny oraz glikemii i insulinemii po podaniu 75 g glukozy doustnie (pole pod krzywą - AUC-GLU,
AUC-IRI) w obwodowej krwi żylnej u otyłych pacjentów przed i po leczeniu bariatrycznym (m = miesiące; x ± SEM; *p < 0,05;
**p < 0,01; ***p < 0,001 v. przed operacją)
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Figure 5. Peripheral blood concentrations of leptin, adiponectin, resistin and ghrelin in obese patients before and after surgery
(m = months; x ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001 vs. before surgery)
Rycina 5. Stężenia: leptyny, adiponektyny, rezystyny i greliny w obwodowej krwi żylnej u otyłych pacjentów przed i po leczeniu
bariatrycznym (m = miesiące; x ± SEM; *p < 0,05; **p < 0,01; ***p < 0,001 v. przed operacją)
Table I. Positive correlations (months after surgery in brackets)
Tabela I. Korelacje dodatnie pomiędzy badanymi parametrami (w nawiasach czas w miesiącach od operacji)
Adiponectin Ghrelin (6, 12); Total Cholesterol (0); HDL (0, 6, 12); LDL (0)
Resistin Ghrelin (0, 24); RR S (24); RR D (0); Waist circumference (3, 24); BMI (3, 24); Triglycerides (24); CRP (24);
Body mass (3, 24); Glucose AUC (12)
Leptin RR S (12); RR D (12); Waist circumference (6, 24); BMI (0, 6, 12); HOMA-IR (12); Body mass (6, 12, 24);
IRI 0’ (12, 24) IRI AUC (0)
Ghrelin RR S (6, 24); RR D (24); HDL (6, 12); Triglycerides (0); CRP (3);
RR S RR D (0, 3, 6, 12, 24); Glucose 0’ (0); Glucose AUC (0, 12)
RR D Glucose AUC (0)
Waist circumference BMI (0, 3, 6, 12, 24); LDL (24); Triglycerides (12, 24); HOMA-IR (6, 12, 24); Body mass (0, 3, 6, 12, 24);
Glucose 0’ (6); IRI 0’ (6, 12, 24)
BMI CRP (24); HOMA-IR (6, 12, 24); Body mass (0, 3, 6, 12, 24); IRI 0’ (6, 12, 24); IRI AUC (12)
Total cholesterol HDL (0); LDL (0, 3, 6, 12, 24); Triglycerides (6, 24);
Triglycerides HOMA-IR (3); Body mass (24; ) Glucose 0’ (0, 3, 24); Glucose AUC (3, 6, 12, 24)
CRP Body mass (24)
HOMA-IR Body mass (6, 12, 24); Glucose 0’ (0, 3, 6, 12); Glucose AUC (0, 3, 6); IRI 0’ (0, 3, 6, 12, 24); IRI AUC (6, 24)
Body mass Glucose 0’ (6, 12, 24); IRI 0’ (6, 12, 24);
Glucose 0’ Glucose AUC (0, 3, 6, 12, 24); IRI 0’ (0, 3, 12)
Glucose AUC IRI 0’ (0, 3, 12); IRI AUC (24)
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tion to convert energy, such as inducing hypothalamic
hypogonadism to prevent fertilisation [45]. Current
studies are investigating the role of leptin in weight-
loss management because persons who have recently
lost weight have relative leptin deficiency that may drive
them to regain weight. Leptin deficiency is also evident
in patients with diet- or exercise-induced hypothalamic
amenorrhea and lipoatrophy [45].
According to a number of case studies, serum leptin
levels decrease with weight loss after bariatric surgery
[46–49]. The decrease in leptin peripheral blood concen-
tration, as observed in our study, was beyond the ex-
pected value based on body composition [47, 50]. In
a case-control study, serum leptin levels were lower in
weight-stable RYGB patients 35 months after surgery,
compared with BMI-matched controls [51]. Given the
putative adipostatic role of leptin, it is possible that rel-
ative hypoleptinaemia may also play a role in weight
regain.
Adiponectin (total and low molecular weight forms)
is another adipocyte-derived cytokine that plays an
important role in regulating energy homeostasis, protects
the arterial wall against atherosclerosis and increases in-
sulin sensitivity. Adiponectin is found in high concen-
trations in the peripheral circulation [52], and its circu-
lating levels are diminished in obese patients and those
with type 2 diabetes [53]. Moreover, adiponectin concen-
tration is inversely associated with central or overall ad-
iposity [54, 55] and is negatively associated with fasting
insulin levels at baseline and may also participate in
a regulation of lipid metabolism at baseline [56].
Resistin, a plasma protein, induces insulin resistance
in rodents. Whereas rodent resistin is made in adipo-
cytes, in humans its major source are the macrophages.
Therefore resistin may be an inflammatory marker of
atherosclerosis in humans [57–59].
For a long time it has been known that obesity is
linked to insulin resistance. In recent years, many in-
vestigators have reported that adipocytes secrete
a group of bioactive peptides called adipocytokines,
which play a pivotal role in energy homeostasis by af-
fecting insulin sensitivity, glucose and lipid metabolism,
food intake and inflammation. Evidence from animal
and human studies suggests that adiponectin plays an
important role in insulin sensitivity [27, 28, 60–62] in-
flammation [63], atherogenesis [64, 65], lipid metabo-
lism [27, 66], and thus influences hyperlipidaemia and
cardiovascular disease [63]. The relationship between
adiponectin and insulin sensitivity has been established
in an animal model in which adiponectin administra-
tion reversed insulin resistance in lipoatrophic mice [26].
Moreover, the levels of adiponectin are lower in patients
with type 2 diabetes or insulin resistance [65, 66] and
higher in humans treated with thiazolidinediones [67,
68]. Adiponectin has recently been observed not to be
a major determinant of weight loss-induced improve-
ments in insulin sensitivity [56].
Although obesity may be linked to resistin, the role
of resistin in humans is still controversial. Conflicting
results of the associations between resistin and BMI and
measures of insulin resistance have been reported. Re-
cent results obtained by Owecki et al. [69] and Yuan et
al. [70] did not reveal any relationship between resistin
concentration and insulin resistance. Others proposed
that resistin plays a role [71, 72] in obesity-mediated
insulin resistance and is also a proinflammatory mole-
cule [53, 73]. Therefore, it seems that resistin may be
linked to inflammation and obesity and, indirectly, to
insulin resistance [74]. Moreover, it has been shown that
increasing levels of leptin, and decreasing levels of ad-
iponectin, correlate [75]) with worsening insulin resis-
tance in obese individuals. Furthermore, it has also been
Table II. Negative correlations (months after surgery in brackets)
Tabela II. Korelacje ujemne pomiędzy badanymi parametrami (w nawiasach czas w miesiącach od operacji)
Adiponectin Resistin (24); Waist circumference (6, 12, 24); BMI (6, 12, 24); Triglycerides (6); HOMA-IR (6);
Body mass (12); Glucose AUC (6); IRI 0’ (6, 12); IRI AUC (6, 12)
Leptin Body mass reduction (12)
Ghrelin HDL (24); Triglycerides (12);
Waist circumference HDL (12, 24); IRI AUC (0)
BMI HDL (12)
Total cholesterol IRI AUC (3)
HDL Triglycerides (6, 12, 24); HOMA-IR (6); Glucose AUC (12); IRI 0’ (6); IRI AUC (12)
LDL IRI AUC (3)
HOMA-IR Body mass reduction (6, 12, 24);
Body mass Glucose AUC (0); IRI AUC (0)
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shown that leptin levels decrease, and adiponectin lev-
els rise, following bariatric surgery. These changes cor-
relate with weight loss and improvement in insulin se-
cretion [75].
Marker of chronic inflammation (CRP) decreased
with time in our subjects treated by VBG, which may
be partly related to a decrease in arterial hypertension
[76] or a decrease of fat mass and increase of adiponec-
tin levels [77].
The changes in energy intake, and perhaps even
energy expenditure, seen after bariatric surgery may be
affected by changes in gut and adipocyte hormones [19].
This 28-aminoacid peptide has been found to be essen-
tial for its effect on the appetite [78]. About two thirds
of circulating ghrelin is thought to be produced by the
stomach, but ghrelin-producing cells have also been
found in the duodenum, ileum, caecum and colon. The
primary regulator of plasma ghrelin levels is thought
to be calorie intake [78]. There is a reversible suppres-
sion of ghrelin associated with obesity, such that ghre-
lin levels normalise after diet-induced weight loss or
after bariatric surgery [78].
Gut hormones such as ghrelin, peptide YY (PYY),
and glucagon-like-peptide (GLP)-1 have an important
role in governing satiety [78]. Of these, ghrelin is an or-
exigenic peptide, secreted primarily by the enteroen-
docrine cells in the fundus of the stomach and acts
through the hypothalamus [79–82]. Ghrelin is a natural
ligand of the growth hormone secretagogue receptor,
and has been demonstrated to enhance appetite, reduce
fat utilisation and promote adiposity following central
or peripheral administration to both rodents and hu-
mans [83]. Serum concentrations of ghrelin typically
increase on fasting and decrease following food intake.
Therefore, abnormal ghrelin regulation may influence
the development of obesity.
Ghrelin levels have been found to increase after GB
surgery [84, 85], although transiently in the case of one
study [83], and suggest a role in weight regain after this
procedure. Gastric secretion of ghrelin may be influ-
enced by numerous factors, such as administration of
glucose and insulin, activation of somatostatin recep-
tors, the cholinergic system, GLP-1 (glucagon-like pep-
tide 1), PYY (peptide YY), oxyntomodulin, thyroid hor-
mones, and testosterone. Ghrelin levels are inversely
related to BMI, with higher values observed in anorex-
ia nervosa and cachexia, and lower levels in obesity. An
exception to this rule is Prader-Willi syndrome, in which
obesity is associated with increased ghrelin concentra-
tions in serum. Changes in body weight are accompa-
nied by changes in ghrelin levels, which increase with
weight loss and decrease with weight gain [78]. Weight
loss in RYGB surgery patients, however, is associated
with a decrease in ghrelin levels, compared with weight
loss after GB, biliopancreatic diversion, or convention-
al weight loss treatment [86–89], and has often been
considered to contribute to the marked efficacy of the
RYGB, compared with other procedures. This finding
has, however, not been universally observed [90, 91].
The conflicting data may be due to the different surgi-
cal techniques that affect the functional integrity of the
gastric fundus from which ghrelin is mostly secreted.
Whether the changes in ghrelin levels in bariatric sur-
gery patients are maintained in the long term should
be evaluated. In patients in our study, the peripheral
blood concentrations of ghrelin increased after VBG.
During VBG surgery, no part of the gastrointestinal
tract acting as a source of adipocytokines was removed.
The positive changes of almost all the post-surgery lab-
oratory and clinical findings are probably related to the
effect of a restriction of food intake. The positive or neg-
ative correlations revealed between insulin, HOMA-IR,
leptin, adiponectin and anthropometric measurements
after vertical banded gastroplasty suggest that a num-
ber of these factors are related to changes of body com-
position and metabolic function of patients receiving
surgical treatment for severe obesity.
Conclusions
1. Vertical banded gastroplasty is still a valuable meth-
od of treating severe obesity leading to significant
decrease of body weight and improvement of the
main parameters of the metabolic syndrome in a few
months after surgery.
2. A partial reverse in anthropometric parameters, as
well as measures of insulin sensitivity, and adipok-
ines at two (and four) years after bariatric surgery
give very promising indications against atheroscle-
rosis and other health risks.
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